Literature DB >> 17374575

Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma.

Huai-Quan Zuo1, Lu-Nan Yan, Yong Zeng, Jia-Ying Yang, Hong-Zhi Luo, Jiang-Wen Liu, Li-Xin Zhou.   

Abstract

BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is a rare subtype of primary liver cancer, and clinicopathological features of cHCC-CC have seldom been reported in detail. This study was undertaken to explore the diagnosis and clinicopathological characteristics of cHCC-CC in comparison with hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), respectively.
METHODS: The clinical data from 15 patients with cHCC-CC, 132 patients with HCC and 44 patients with CC who had undergone hepatic resection were analyzed retrospectively. Clinicopathological characteristics of cHCC-CC, HCC and CC such as hepatitis B viral infection, serum hepatitis C virus (HCV) antibody, serum alpha-fetoprotein (AFP) level, cirrhosis, vascular invasion, lymph node metastasis, surgical procedure and adjuvant treatment were also analyzed. Follow up was carried out in the patients, and their 1-, 3-, and 5-year survival rates were calculated.
RESULTS: Two patients with cHCC-CC were correctly diagnosed by enhanced CT before operation, the other 13 patients were diagnosed by histology and immunohistochemistry after operation. Radical (8/15) and conservative hepatectomy (7/15) for cHCC-CC was similar to that for HCC and CC (P>0.05). Pathologically cHCC-CC showed more significantly vascular invasion and lymph node metastasis than HCC (P<0.05), and a similarity to CC (P>0.05). Hepatitis B viral infection, serum HCV antibody, cirrhosis, and serum AFP level of cHCC-CC patients were similar to those of HCC patients (P>0.05) but different from CC patients (P<0.05). The cumulative 1-, 3-, and 5-year survival rates in patients with cHCC-CC were poorer than in patients with HCC or CC (P<0.05).
CONCLUSIONS: Patients with cHCC-CC are seldom diagnosed before operation. The progression of cHCC-CC is more rapid than that of HCC or CC. Survival rate of patients with cHCC-CC after hepatic resection is poorer than that of patients with HCC or CC.

Entities:  

Mesh:

Year:  2007        PMID: 17374575

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  21 in total

1.  Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes.

Authors:  Ruidong Xue; Lu Chen; Chong Zhang; Masashi Fujita; Ruoyan Li; Shu-Mei Yan; Choon Kiat Ong; Xiwen Liao; Qiang Gao; Shota Sasagawa; Yanmeng Li; Jincheng Wang; Hua Guo; Qi-Tao Huang; Qian Zhong; Jing Tan; Lisha Qi; Wenchen Gong; Zhixian Hong; Meng Li; Jingmin Zhao; Tao Peng; Yinying Lu; Kiat Hon Tony Lim; Arnoud Boot; Atushi Ono; Kazuaki Chayama; Zemin Zhang; Steve George Rozen; Bin Tean Teh; Xin Wei Wang; Hidewaki Nakagawa; Mu-Sheng Zeng; Fan Bai; Ning Zhang
Journal:  Cancer Cell       Date:  2019-05-23       Impact factor: 31.743

Review 2.  Combined hepatocellular and cholangiocarcinoma associated with hepatolithiasis: report of a case.

Authors:  Kemal Deniz; Edip Torun; Mehmet Celikbilek; Erdoğan Sözüer
Journal:  Surg Today       Date:  2011-03-23       Impact factor: 2.549

3.  Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu-Peng Wu; Cheng-Jun Sui; Jia-Mei Yang
Journal:  World J Gastroenterol       Date:  2014-09-21       Impact factor: 5.742

4.  Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.

Authors:  Mitsumaro Itoyama; Masaki Hata; Koji Yamanegi; Naoko Yamada; Hideki Ohyama; Hiroshi Hirano; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2012-03-20       Impact factor: 2.309

5.  Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.

Authors:  Vincenzo Cardinale; Rossella Semeraro; Alessia Torrice; Manuela Gatto; Cristina Napoli; Maria Consiglia Bragazzi; Raffaele Gentile; Domenico Alvaro
Journal:  World J Gastrointest Oncol       Date:  2010-11-15

Review 6.  Surgical Treatment of Hepatocholangiocarcinoma: A Systematic Review.

Authors:  Damiano Gentile; Matteo Donadon; Ana Lleo; Alessio Aghemo; Massimo Roncalli; Luca di Tommaso; Guido Torzilli
Journal:  Liver Cancer       Date:  2019-11-01       Impact factor: 11.740

Review 7.  Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review.

Authors:  Sirio Fiorino; Letizia Bacchi-Reggiani; Dario de Biase; Adele Fornelli; Michele Masetti; Andrea Tura; Fabio Grizzi; Matteo Zanello; Laura Mastrangelo; Raffaele Lombardi; Giorgia Acquaviva; Luca di Tommaso; Arrigo Bondi; Michela Visani; Sergio Sabbatani; Laura Pontoriero; Carlo Fabbri; Andrea Cuppini; Annalisa Pession; Elio Jovine
Journal:  World J Gastroenterol       Date:  2015-12-07       Impact factor: 5.742

8.  An update on long-term outcome of curative hepatic resection for hepatocholangiocarcinoma.

Authors:  Kenneth Siu-Ho Chok; Kelvin K C Ng; Tan To Cheung; Wai Key Yuen; Ronnie T P Poon; Chung Mau Lo; Sheung Tat Fan
Journal:  World J Surg       Date:  2009-09       Impact factor: 3.352

9.  Outcome of combined hepatocellular and cholangiocarcinoma of the liver.

Authors:  Jue Wang; Fenwei Wang; Anne Kessinger
Journal:  J Oncol       Date:  2010-09-02       Impact factor: 4.375

10.  Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy.

Authors:  Jing Yu; Xi Zhang; Qiyue Huang; Sirui Tan; Xianze Xiong; Hongfeng Gou
Journal:  Cancer Manag Res       Date:  2021-05-31       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.